Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Diagnostics » Molecular Diagnostics » Epic Sciences' Circulating Tumor Cell Prostate Cancer Test Shows Promise in New JAMA Study

Epic Sciences' Circulating Tumor Cell Prostate Cancer Test Shows Promise in New JAMA Study

Jun 06, 2016
|
Molika Ashford
Premium

CHICAGO (GenomeWeb) – A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR-V7 protein expression test using Epic Sciences' non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration-resistant prostate cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Finds a Whole Bunch

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Away From the Field

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

PNAS Studies Look at Bacterial Detection Probes, Cholera Culprit Evolution in Environment, More

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

In a Different Lab

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Molecular Diagnostics

  1. Qiagen Receives FDA Emergency Use Authorization for SARS-CoV-2 Respiratory Panel

  2. Abbott POC Coronavirus Test Snares FDA Emergency Use Authorization

  3. Bio-Rad Laboratories ddPCR Shows Accuracy Benefits in COVID-19 Detection Studies

  4. Cue Health Awarded $13M BARDA Contract for POC Coronavirus Test

  5. Exact Sciences, Promega Aiding in COVID-19 Testing in Wisconsin

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.